These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35184718)

  • 1. A Review on the New Indication of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in the Treatment of Coronavirus Disease 2019.
    Karbasforooshan H; Salari S; Hosseinjani H
    Infect Disord Drug Targets; 2022; 22(5):e180222201281. PubMed ID: 35184718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.
    Cihlar T; Ray AS
    Antiviral Res; 2010 Jan; 85(1):39-58. PubMed ID: 19887088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.
    Feng JY; Du Pont V; Babusis D; Gordon CJ; Tchesnokov EP; Perry JK; Duong V; Vijjapurapu A; Zhao X; Chan J; Cohen C; Juneja K; Cihlar T; Götte M; Bilello JP
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure, Synthesis and Inhibition Mechanism of Nucleoside Analogues as HIV-1 Reverse Transcriptase Inhibitors (NRTIs).
    Yoshida Y; Honma M; Kimura Y; Abe H
    ChemMedChem; 2021 Mar; 16(5):743-766. PubMed ID: 33230979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.
    Hukezalie KR; Thumati NR; Côté HC; Wong JM
    PLoS One; 2012; 7(11):e47505. PubMed ID: 23166583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors].
    Bonora S; Calcagno A; Gonzalez de Requena D; Bargiacchi O; Di Perri G
    Infez Med; 2006 Jun; 14(2):61-70. PubMed ID: 16891850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).
    Parang K; El-Sayed NS; Kazeminy AJ; Tiwari RK
    Molecules; 2020 May; 25(10):. PubMed ID: 32429580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and biological aspects of basic research on nucleoside-based reverse transcriptase inhibitors.
    Macchi B; Mastino A
    Pharmacol Res; 2002 Dec; 46(6):473-82. PubMed ID: 12457619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
    Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
    Diamond TL; Ngo W; Xu M; Goh SL; Rodriguez S; Lai MT; Asante-Appiah E; Grobler JA
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0013322. PubMed ID: 35546110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity.
    Vinogradov SV; Poluektova LY; Makarov E; Gerson T; Senanayake MT
    Antivir Chem Chemother; 2010 Oct; 21(1):1-14. PubMed ID: 21045256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics.
    Holec AD; Mandal S; Prathipati PK; Destache CJ
    Curr HIV Res; 2017; 15(6):411-421. PubMed ID: 29165087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
    Imaz A; Llibre JM; Mora M; Mateo G; Camacho A; Blanco JR; Curran A; Santos JR; Caballero E; Bravo I; Gayá F; Domingo P; Rivero A; Falcó V; Clotet B; Ribera E
    J Antimicrob Chemother; 2011 Feb; 66(2):358-62. PubMed ID: 21172789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase.
    Isel C; Ehresmann C; Walter P; Ehresmann B; Marquet R
    J Biol Chem; 2001 Dec; 276(52):48725-32. PubMed ID: 11668180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.
    Painter GR; Almond MR; Mao S; Liotta DC
    Curr Top Med Chem; 2004; 4(10):1035-44. PubMed ID: 15193137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
    De Clercq E
    Adv Pharmacol; 2013; 67():317-58. PubMed ID: 23886005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy.
    Balzarini J
    Biochem Pharmacol; 1999 Jul; 58(1):1-27. PubMed ID: 10403515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.